Veliparib Hydrochloride

N/A

Report date: 2026/05/18 20:02:07
NME

Base Information

Drug NameVeliparib Hydrochloride
Drug Alias NameVeliparib维利帕利Veliparibum盐酸维利帕尼盐酸维利帕li +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) polymerase 1 inhibitorsPoly (ADP-Ribose) Polymerase 2 inhibitors
TargetsPoly (ADP-Ribose) Polymerase 2Poly (ADP-Ribose) polymerase 1
Therapy Area/IndicationsPancreatic neuroendocrine tumors (pNET)Brain metastasesMetastatic breast cancer +[128] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[48] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaIND
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesGeorgetown UniversityNational Cancer InstituteAbbvie Inc +[4] 
Inactive CompaniesAbbott LaboratoriesNational Institutes Of Health Clinical Center (Cc)University Medical Center Groningen +[9] 
Active IndicationsBrain metastasesMetastatic breast cancerSolid tumours +[37] 
Inactive IndicationsPancreatic neuroendocrine tumors (pNET)CNS Embryonal TumorAngioimmunoblastic T-cell Lymphoma +[91] 

Other Information

ATC CodeL01XK05
Related LinksWikipediaDrugBankKEGG